French HIV-HBV Cohort

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

152 participants

Study Classification

OBSERVATIONAL

Study Start Date

2016-10-31

Study Completion Date

2018-09-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overarching purpose of this study is to further understand the reasons for and clinical implications of persistent HBV infection in patients co-infected with HIV and HBV in the era of highly effective antiviral treatment against both viruses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Application of HBV Rapid Tests as a Tool for Wide-Use Screening

NCT01767597

Hepatitis B Liver Cirrhosis Carcinoma, Hepatocellular

COMPLETED NA

Descriptive Analysis of Changes in Hepatitis B Markers in People Living With HIV on Injectable Therapy.

NCT06421259

Hiv Infection Hepatitis B

NOT_YET_RECRUITING

HIV-HBV Co-Infection and Liver Disease

NCT00637429

HIV Infections HIV-HBV Co-Infection

UNKNOWN

Towards a Functional Cure for HBV - The COMMIT Cohort Study

NCT03645044

Hiv HBV Coinfection

ACTIVE_NOT_RECRUITING

Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses

NCT06338826

HIV Infections HBV Coinfection

NOT_YET_RECRUITING PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The French HIV-HBV Cohort is an observational, non-interventional study including 308 HIV-infected patients with chronic HBV infection (HBsAg-positive serology \>6 months) in seven clinical centers. Patients were recruited in 2002-2003 and followed prospectively every three to twelve months, during two phases, until 2010-2011. Extensive information on a variety of HIV- and HBV-related parameters were collected during these study visits.

This particular study aims to extend follow-up of the French HIV-HBV Cohort using a different type of design. Patients who completed at least one study phase of the French HIV-HBV Cohort are selected for participation. Patients continuing follow-up at a participating clinical center are asked to undergo their routine clinical visit, during which time medical data from the years since last cohort visit until their routine visit are extracted. For those who died, information from the years since last cohort visit until death will be collected.

The primary objective for this cohort extension is to further understand the reasons for and clinical implications of persistent HBV infection in patients co-infected with HIV and HBV in the era of highly effective antiviral treatment against both viruses.

The following secondary objectives are as follows:

* To establish the extent of persistent viremia (PV) of HBV, quantified either in serum or within the hepatocyte
* To understand whether this persistence effects clinically-relevant serological outcomes (i.e. HBeAg and HBsAg seroclearance and seroconversion along with HBsAg quantification) after prolonged follow-up
* To quantify the evolution of liver fibrosis using non-invasive methods and, in a small subset of patients, liver biopsies, while investigating the virological and immunological factors associated with its progression and regression
* To describe the causes of liver-related and non-liver-related morbidity and mortality and the direct effect of persistent HBV DNA replication on these outcomes

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hepatitis B HIV Liver Cirrhosis End Stage Liver Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

OTHER

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

HIV-HBV co-infected individuals

No interventions will be administered. Individuals will be undergoing routine care.

Routine care

Intervention Type OTHER

Routine care recommended for patients co-infected with HIV and hepatitis B virus (per European Association for the Study of the Liver and European AIDS Clinical Society guidelines).

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Routine care

Routine care recommended for patients co-infected with HIV and hepatitis B virus (per European Association for the Study of the Liver and European AIDS Clinical Society guidelines).

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* HBsAg seropositivity for \>6 months (at initial cohort inclusion)
* HIV-positive serology confirmed with Western blot (at initial cohort inclusion)
* Karnofsky score \>70 (at initial cohort inclusion)
* Age ≥18 years old (at initial cohort inclusion)
* Completed follow-up in at least one previous study phase of the French HIV-HBV Cohort
* Obtained signed written informed consent